This position has been filled.
University of Pittsburgh Medical Center (UPMC) is an integrated health system with nearly $13 billion in operating revenue in 2016. UPMC is tightly integrated with the University of Pittsburgh and its School of Medicine. UPMC is the dominant provider in the region and is the second largest provider-owned health plan in the country with more than 3 million subscribers. UPMC has an unusual commitment to research and its investment of clinical revenue into the Medical School has built the University of Pittsburgh into a research powerhouse which now ranks 5th in NIH funding amongst universities.
Cancer care is a high priority focus for the Medical School and for UPMC. Cancer care and basic and clinical research are accomplished jointly by the University of Pittsburgh Cancer Institute (UPCI) and the UPMC Cancer Center. The UPCI is part of the University of Pittsburgh Medical School and is an NCI-designated comprehensive cancer center. UPMC Cancer Center, which is the primary clinical arm of cancer care for UPMC, is the dominant outpatient and inpatient cancer care provider/network in the tristate (Pennsylvania, Ohio, West Virginia) region. This close and synergistic partnership allows academic researchers to focus on research while simultaneously having access to a large patient population for enrollment in interventional and observational clinical trials.
UPCI is seeking a Director of Clinical Research in Hematologic Malignancy to build the critical mass of faculty and investigative activities necessary to develop a sustainable, grant-funded and productive hematologic malignancy program. This newly created role will organize existing faculty, assist in identifying and recruiting additional junior faculty, set priorities, attract industry trials, and develop investigator-initiated trials. Director of Clinical Research in Hematologic Malignancy is seen as critical to UPCI’s success in developing a portfolio of clinical trials that spans early stage promising drugs to larger scale phase II/III with drugs likely to be approved.
- MD, Board certified in Hematology and/or Oncology
- Candidates qualified for appointment at the Associate Professor or Professor rank.
- Experience leading clinical trials is required.
- Prior clinical research experience in hematologic malignancies.
- Immunotherapy experience is preferred.